ClinicalTrials.gov record
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age

ClinicalTrials.gov ID: NCT05630846

Public ClinicalTrials.gov record NCT05630846. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 1:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II, Single-blind, Randomized, Controlled Study to Evaluate the Immunogenicity and Safety of a Measles, Mumps, Rubella, Varicella Vaccine Compared With ProQuad, Administered in Healthy Children 4-6 Years of Age

Study identification

NCT ID
NCT05630846
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
801 participants

Conditions and interventions

Interventions

  • Investigational M(L)M(L)R(L)V(L)NS vaccine Biological
  • Investigational MM(H)RVNS vaccine Biological
  • Investigational MMRV(H)NS vaccine Biological
  • Marketed MMRV_Lot 1 and Lot 2 vaccine Biological

Biological

Eligibility (public fields only)

Age range
4 Years to 6 Years
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 13, 2022
Primary completion
Jun 6, 2024
Completion
Oct 13, 2024
Last update posted
Jun 21, 2025

2022 – 2024

United States locations

U.S. sites
35
U.S. states
16
U.S. cities
33
Facility City State ZIP Site status
GSK Investigational Site Birmingham Alabama 35235
GSK Investigational Site Jonesboro Arkansas 72401
GSK Investigational Site Bellflower California 90706
GSK Investigational Site Huntington Park California 90255
GSK Investigational Site Oakland California 94611
GSK Investigational Site Roseville California 95661
GSK Investigational Site Sacramento California 95815
GSK Investigational Site Sacramento California 95823
GSK Investigational Site San Jose California 95119
GSK Investigational Site Santa Clara California 95051
GSK Investigational Site West Covina California 91790
GSK Investigational Site Miami Lakes Florida 33014
GSK Investigational Site Tampa Florida 33613
GSK Investigational Site Ammon Idaho 83406
GSK Investigational Site Idaho Falls Idaho 83404
GSK Investigational Site Louisville Kentucky 40291
GSK Investigational Site Lafayette Louisiana 70508
GSK Investigational Site Boston Massachusetts 02118
GSK Investigational Site Bingham Farms Michigan 48025
GSK Investigational Site Detroit Michigan 48201
GSK Investigational Site Lincoln Nebraska 68505
GSK Investigational Site Lincoln Nebraska 68522
GSK Investigational Site Omaha Nebraska 68114
GSK Investigational Site Syracuse New York 13210
GSK Investigational Site Cleveland Ohio 44121
GSK Investigational Site Dayton Ohio 45414
GSK Investigational Site Simpsonville South Carolina 29681
GSK Investigational Site Tullahoma Tennessee 37388
GSK Investigational Site Dickinson Texas 77539
GSK Investigational Site McAllen Texas 78504
GSK Investigational Site Richmond Texas 77469
GSK Investigational Site Layton Utah 84041
GSK Investigational Site Provo Utah 84604
GSK Investigational Site Roy Utah 84067
GSK Investigational Site South Jordan Utah 84095

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 12 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05630846, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 21, 2025 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05630846 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →